Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Hypertension, Pulmonary
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Hypertension » Hypertension, Pulmonary
Description
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. MeSH
Hierarchy View
Subtype Terms (3)
Familial Primary Pulmonary Hypertension
21 drugs (16 approved, 5 experimental)
Persistent Fetal Circulation Syndrome
10 drugs (8 approved, 2 experimental)
Pulmonary Arterial Hypertension
94 drugs (49 approved, 45 experimental)
Phase 4 Indicated Drugs (17)
Phase 3 Indicated Drugs (20)
Other Experimental Indicated Drugs (13)
Organization Involved with Phase 4 Indications (64)
All India Institute of Medical Sciences
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Dr. Robert Klempfner Heart Rehabilitation Institute
Fundación de Investigación en Red en Enfermedades Cardiovasculares
Kerckoff clinic, Bad Nauheim, Germany
National Center for Research Resources (NCRR)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of General Medical Sciences (NIGMS)
The University of Texas, Dallas
University of Alabama, Birmingham
University of British Columbia
University of California, Los Angeles
University of California, San Diego
Organization Involved with Phase 3 Indications (96)
Canadian Institutes of Health Research (CIHR)
Cardiothoracic Surgical Group of Chinese Society of Pediatric Surgery
Case Western Reserve University
Center for Health, Exercise and Sport Sciences, Serbia
Hannover Clinical Trial Center GmbH
Health Sciences Centre Foundation, Manitoba
Huazhong University of Science and Technology
Interstitial Lung Disease Study Group, Korea
Italian Association of Hospital Pneumologists
Jiangsu Carefree Pharmaceutical Co., Ltd.
Justus Liebig University Giessen
National Institute of Child Health and Human Development (NICHD)
New England Research Institutes
Nuventra Pharma Sciences, Inc.
Papworth Hospital NHS Foundation Trust
Shields, Shields and Associates
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Universidad Autonoma de Barcelona
Organization Involved with Phase 2 Indications (57)
Autonomous University of Madrid
Canadian Anesthesiologists' Society
Heart and stoke fondation of Quebec
Instituto Mexicano del Seguro Social
International CTEPH Association
National Hospital Organisation Nagoya Medical Centre
National Hospital Organization Okayama Medical Center
National Institute on Aging (NIA)
State University of New York, Buffalo
The Cardiovascular Medical Research and Education Fund
Organization Involved with Phase 1 Indications (20)
Organization Involved with Other Experimental Indications (23)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
